Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ucp2 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the uncoupling protein 2 (UCP2) gene. UCP2 is an anion carrier protein located in the mitochondrial inner membrane that plays a critical role in energy metabolism and the regulation of immune cell fate. In research settings, Ucp2 siRNA is utilized to investigate the functional consequences of UCP2 deficiency, particularly in T cells. Studies have demonstrated that silencing UCP2 in CD4+ T cells leads to a significant shift in the Th2/Th1 ratio, promoting a pathogenic phenotype characterized by increased production of nitric oxide (NO) and inducible nitric oxide synthase (iNOS). This tool is primarily used in preclinical research models, such as murine melanoma and experimental autoimmune encephalomyelitis (EAE), to elucidate the metabolic pathways governing immune responses and potential therapeutic targets for inflammatory and neoplastic diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ucp2 sirna.